全文获取类型
收费全文 | 60103篇 |
免费 | 4814篇 |
国内免费 | 201篇 |
专业分类
耳鼻咽喉 | 686篇 |
儿科学 | 1480篇 |
妇产科学 | 940篇 |
基础医学 | 7393篇 |
口腔科学 | 1462篇 |
临床医学 | 6577篇 |
内科学 | 13692篇 |
皮肤病学 | 1171篇 |
神经病学 | 5026篇 |
特种医学 | 2132篇 |
外国民族医学 | 1篇 |
外科学 | 8534篇 |
综合类 | 902篇 |
一般理论 | 41篇 |
预防医学 | 5485篇 |
眼科学 | 1128篇 |
药学 | 4565篇 |
1篇 | |
中国医学 | 83篇 |
肿瘤学 | 3819篇 |
出版年
2023年 | 242篇 |
2021年 | 978篇 |
2020年 | 581篇 |
2019年 | 957篇 |
2018年 | 1108篇 |
2017年 | 821篇 |
2016年 | 917篇 |
2015年 | 1027篇 |
2014年 | 1535篇 |
2013年 | 2326篇 |
2012年 | 3416篇 |
2011年 | 3471篇 |
2010年 | 1939篇 |
2009年 | 1763篇 |
2008年 | 3295篇 |
2007年 | 3529篇 |
2006年 | 3622篇 |
2005年 | 3555篇 |
2004年 | 3425篇 |
2003年 | 3295篇 |
2002年 | 3220篇 |
2001年 | 1233篇 |
2000年 | 1192篇 |
1999年 | 1165篇 |
1998年 | 785篇 |
1997年 | 635篇 |
1996年 | 605篇 |
1995年 | 598篇 |
1994年 | 516篇 |
1993年 | 485篇 |
1992年 | 810篇 |
1991年 | 790篇 |
1990年 | 737篇 |
1989年 | 661篇 |
1988年 | 631篇 |
1987年 | 642篇 |
1986年 | 610篇 |
1985年 | 633篇 |
1984年 | 601篇 |
1983年 | 520篇 |
1982年 | 544篇 |
1981年 | 480篇 |
1980年 | 398篇 |
1979年 | 428篇 |
1978年 | 390篇 |
1977年 | 342篇 |
1976年 | 295篇 |
1975年 | 271篇 |
1974年 | 308篇 |
1973年 | 280篇 |
排序方式: 共有10000条查询结果,搜索用时 437 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
3.
Phoebe Hammer Kevin White Stephanie Mengden Vessy Korcheva Philipp W. Raess 《Journal of cutaneous pathology》2019,46(5):343-346
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances. 相似文献
4.
Tonya J.H. White 《Journal of the American Academy of Child and Adolescent Psychiatry》2019,58(11):1042-1050
5.
6.
7.
8.
Nicole D. Facompre Pavithra Rajagopalan Varun Sahu Alexander T. Pearson Kathleen T. Montone Claire D. James Frederico O. Gleber-Netto Gregory S. Weinstein Jalal Jalaly Alexander Lin Anil K. Rustgi Hiroshi Nakagawa Joseph A. Califano Curtis R. Pickering Elizabeth A. White Bradford E. Windle Iain M. Morgan Roger B. Cohen Phyllis A. Gimotty Devraj Basu 《International journal of cancer. Journal international du cancer》2020,147(11):3236-3249
9.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
10.
Jamaal L. Benjamin MD PhD Rebecca Dennis DO Stacy White Jr MD David Munson MD Sudha A. Anupindi MD Maciej Piskunowicz MD Kassa Darge MD PhD Ami Gokli MD Misun Hwang MD 《Journal of ultrasound in medicine》2020,39(5):1031-1036
Bowel diseases of prematurity, including necrotizing enterocolitis, are dreaded ailments of neonates. Early diagnosis is difficult, with clinical and radiographic findings often inconclusive. We present a novel use of contrast-enhanced ultrasound in detection of pediatric bowel disease. Early identification of compromised blood flow or an at-risk bowel can be quantitatively detected and monitored. This ability has implications for guidance of emerging therapies, allowing targeting of inflammation. These findings represent an advancement in detection of bowel disease in neonates. 相似文献